Fig. 2

MYC-regulated genes in the WNT pathway are upregulated in cancer. a Comparison of the levels of the indicated genes in cancer tissues and adjacent normal tissues from TCGA database. Blue: downregulated (< 0.7), grey: No change (0.7–1.3), and red: upregulated (> 1.3), N = 41 pairs. b Kaplan–Meier curve comparing survival of patients with colon adenocarcinoma (COAD) and high or low levels of LEF1. Comparison between 30% highest and 30% lowest expression were generated using ONCLnc (http://www.oncolnc.org/). c HCEC expressing control vector, truncated APC, or constitutively activated KRas were transfected with control or MYC siRNAs, and total proteins were extracted with NP40 lysing buffer for Western blotting with the indicated antibodies. d-g RKO (d), DLD1 (e), Huh7 (f), and Colo357 cells (g) were transfected with control or MYC siRNAs, and total proteins were extracted with NP40 lysing buffer for Western blotting with the indicated antibodies. h DLD1 cells were transfected with either control or MYC siRNAs, and the relative RNA levels were measured by using RT-qPCR. Expression levels of each gene was normalized to the levels of 18S, and expression levels of each gene in the control siRNA samples was set to 1. i Identification of the MYC-specific binding motif E-Box in the promoter regions of human, mouse, and rat LEF1. Canonical EBox (CACGTG), non-canonical EBox (CACGCG, CAAGTG, or CACCTG). j ChIP for MYC (Y69 antibody) on the promoter regions of LEF1 and surrounding upstream region that do not contain Eboxes (− 2.6-kb) in DLD1 cells. Fold enrichment for MYC immunoprecipitation in comparison with control was determined by qPCR. * p < 0.05, ** p < 0.01, *** p < 0.001